Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01648140 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging of GSK2336805 in Combination Therapy
A Phase 2 study of Hepatitis C, Chronic, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
- 20
- Study locations
NCT01648140 is a Phase 2 study of Hepatitis C, Chronic that has completed, run by GlaxoSmithKline. The registered enrollment target is 286 participants, below the 365-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT01648140, a Phase 2 study of Hepatitis C, Chronic, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
- 20
- Study locations
Study Summary
GSK2336805 is a novel hepatitis C virus (HCV) non-structural 5A (NS5A) inhibitor being developed for the treatment of chronic HCV infection. This Phase II, multicenter, parallel-group, randomized, dose-ranging study will assess the safety and tolerability, antiviral activity, and pharmacokinetics of GSK2336805 at 2 dose levels (40 and 60 mg) in combination with pegylated interferon alfa-2a (PEG) and ribavirin (RIBA) in approximately 100 treatment-naïve subjects with chronic genotype 1 HCV infection. In a separate nonrandomized single-arm cohort, up to 15 treatment-naïve subjects with genotype 4 chronic HCV infection will be enrolled in parallel at the dose level of 60 mg of GSK2336805.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG Telaprevir
- DRUG GSK2336805 40 mg
- DRUG GSK2336805 60 mg
- DRUG Pegylated interferon alpha-2a
Study Locations (20)
California
- GSK Investigational Site - Anaheim
- GSK Investigational Site - Los Angeles
Florida
- GSK Investigational Site - DeLand
- GSK Investigational Site - Orlando
Georgia
- GSK Investigational Site - Columbus
- GSK Investigational Site - Savannah
Massachusetts
- GSK Investigational Site - Brockton
- GSK Investigational Site - Springfield
North Carolina
- GSK Investigational Site - Asheville
- GSK Investigational Site - Fayetteville
Virginia
- GSK Investigational Site - Annandale
- GSK Investigational Site - Norfolk
Other
- GSK Investigational Site - Brussels
- GSK Investigational Site - Liège
Alabama
- GSK Investigational Site - Dothan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2012-08-01 |
| Est. Completion | 2014-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01648140
The ClinicalTrials.gov registry entry for NCT01648140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 365-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (22% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 5 interventions - of which Ribavirin is the first listed.
NCT01648140 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01648140 about?
NCT01648140 is a clinical study titled "Dose Ranging of GSK2336805 in Combination Therapy". GSK2336805 is a novel hepatitis C virus (HCV) non-structural 5A (NS5A) inhibitor being developed for the treatment of chronic HCV infection. This Phase II, multicenter, parallel-group, randomized, dose-ranging study will assess the safety and tolerability, antiviral activity, and pharmacokinetics of...
What is the current status of trial NCT01648140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2012-08-01. Estimated completion is 2014-07-16.
What conditions does trial NCT01648140 study?
This clinical trial studies the following conditions: Hepatitis C, Chronic.
What interventions are being tested in trial NCT01648140?
The interventions under investigation include: Ribavirin (DRUG), Telaprevir (DRUG), GSK2336805 40 mg (DRUG), GSK2336805 60 mg (DRUG), Pegylated interferon alpha-2a (DRUG).
Who is sponsoring clinical trial NCT01648140?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01648140 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
-
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
COMPLETED · Phase 2
-
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 2
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
COMPLETED · Phase 2
-
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.